CARE reaffirms Zim Labs at BBB, outlook revised to Negative
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.1 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CARE Ratings reaffirmed Zim Laboratories' long-term bank facilities of Rs 127.48 Cr at BBB and short-term facilities of Rs 12 Cr at A3. However, the outlook on the long-term rating was revised from Stable to Negative, signalling potential concern about future credit quality. The current rating stands, but a negative outlook warns of a possible downgrade if conditions worsen.
Negative outlook hints at higher perceived credit risk; may raise borrowing costs and weigh on investor sentiment.